SEC Form 4 · accession 0001209191-15-013100
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Kemmerer
Officer — VP, Pharma Dev & Manufacturing
Period of report
Feb 10, 2015
Accepted (ET)
Feb 12, 2015 · 8:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.79 | Feb 10, 2015 | A | 42,350 | A | — | Feb 10, 2025 | Common Stock | 42,350 | 42,350 | D |
Explanation of responses
- F1Option shares vest and become exercisable in 48 equal monthly installments measured from the vesting commencement date, February 10, 2015.